Celltrion, a South Korean biopharmaceutical company, announced on October 10, 2025, that its biosimilar drug Idenzent (CT-P42), a counterpart to the blockbuster eye treatment Eylea (aflibercept), has received approval from the U.S. Food and Drug Administration (FDA). The approval marks a significant milestone for Celltrion, enabling the company to enter the world’s largest pharmaceutical market with a drug already authorized in South Korea, Europe, and Australia.The FDA greenlit Idenzent in two formulations: vials and pre-filled syringes (PFS). The biosimilar is approved for the full range of
Pharma & Biotech
Lim Hye Jung, HEALTH IN NEWS TEAM
2025.10.10 15:25
